GABA-A Agonists for Epilepsy
Epilepsy is a widespread disease causing a low quality of life. Over 4.1 million people in the developed world alone suffer from epilepsy. 30% of these are unable to achieve satisfactory seizure control with existing treatments.
Most of the remaining 70% are forced to tolerate significant side-effects including sexual dysfunction, sedation, anemia and others. All existing epilepsy drugs cause birth defects.
Bionomics has long been a leader in the field of epilepsy therapy. Indeed, it was the first company in the world to develop a genetic test for epilepsy. Two of Bionomics' epilepsy tests are now available to physicians through leading diagnostics companies.
Bionomics is applying its epilepsy expertise for the development of a new generation of epilepsy treatments based upon modulators of the GABA-A receptor.
These activities have led to identification of a series of compounds that demonstrate exceptional seizure control with an improved side-effects profile.
